Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free ABVX Stock Alerts

Abivax (ABVX) Financials

Abivax logo
$125.91 -0.63 (-0.50%)
As of 12:44 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Abivax

Annual Income Statements for Abivax

This table shows Abivax's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -48 -65 -163 -182 -394
Consolidated Net Income / (Loss)		 -48 -65 -163 -182 -394
Net Income / (Loss) Continuing Operations		 -48 -65 -163 -182 -394
Total Pre-Tax Income 		-48 -65 -163 -182 -388
Total Operating Income		 -47 -69 -141 -179 -289
Total Gross Profit		 0.00 0.00 -7.11 -6.16 -6.10
Total Revenue		 0.00 0.00 -7.11 -6.16 -6.10
Operating Revenue		 0.00 0.00 -7.11 -6.16 -6.10
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 47 69 134 173 283
Selling, General & Admin Expense		 6.32 8.01 25 34 79
Research & Development Expense		 54 52 114 152 209
Other Operating Expenses / (Income)		 -14 -4.90 -5.11 -13 -5.36
Total Other Income / (Expense), net		 -1.19 4.38 -23 -3.37 -99
Interest Expense		 4.03 7.51 31 18 131
Interest & Investment Income		 2.84 12 8.31 14 32
Income Tax Expense		 0.00 0.00 0.00 0.00 6.86
Weighted Average Basic Shares Outstanding		 15.46M 19.09M 43.07M 63.05M 69.53M
Diluted Earnings per Share		 ($2.75) ($3.40) ($3.79) ($2.90) ($5.67)
Weighted Average Diluted Shares Outstanding		 15.46M 19.09M 43.07M 63.05M 69.53M
Weighted Average Basic & Diluted Shares Outstanding		 - - 62.93M 63.35M 78.54M

Quarterly Income Statements for Abivax

No quarterly income statements for Abivax are available.

Annual Cash Flow Statements for Abivax

This table details how cash moves in and out of Abivax's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 36 -68 -163 -112 -354
Net Cash From Operating Activities		 -51 -58 -147 -154 -362
Net Cash From Continuing Operating Activities		 -51 -58 -147 -154 -362
Net Income / (Loss) Continuing Operations		 -48 -65 -163 -182 -394
Consolidated Net Income / (Loss)		 -48 -65 -163 -182 -394
Depreciation Expense		 0.34 0.52 0.78 1.14 1.26
Non-Cash Adjustments To Reconcile Net Income		 -1.70 6.16 11 26 28
Changes in Operating Assets and Liabilities, net		 -1.57 0.08 4.14 1.47 3.31
Net Cash From Investing Activities		 -7.05 0.33 -16 -0.66 8.26
Net Cash From Continuing Investing Activities		 -0.05 0.33 -16 -0.66 8.26
Sale of Property, Plant & Equipment		 - 0.33 -16 - 8.26
Net Cash From Financing Activities		 94 -10 0.00 38 0.00
Net Cash From Continuing Financing Activities		 72 -10 0.00 38 0.00
Issuance of Debt		 - 0.00 0.00 50 0.00
Cash Interest Received		 - 0.02 2.65 8.47 6.49

Quarterly Cash Flow Statements for Abivax

No quarterly cash flow statements for Abivax are available.

Annual Balance Sheets for Abivax

This table presents Abivax's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 124 81 362 212 686
Total Current Assets		 85 39 306 169 622
Cash & Equivalents		 69 29 279 149 606
Accounts Receivable		 17 9.88 27 20 15
Plant, Property, & Equipment, net		 0.23 -0.80 -5.78 -3.51 -60
Plant, Property & Equipment, gross		 0.23 -0.80 -5.78 -3.51 -60
Total Noncurrent Assets		 74 105 218 220 456
Goodwill		 36 20 20 19 22
Intangible Assets		 48 72 171 189 402
Noncurrent Deferred & Refundable Income Taxes		 -0.18 -0.14 -0.06 0.00 0.00
Other Noncurrent Operating Assets		 -9.72 13 27 11 32
Total Liabilities & Shareholders' Equity		 124 143 518 385 1,018
Total Liabilities		 83 70 138 160 89
Total Current Liabilities		 24 38 88 69 44
Short-Term Debt		 0.71 21 33 22 0.00
Accounts Payable		 23 17 52 45 44
Other Current Liabilities		 0.00 0.00 2.85 1.21 0.00
Total Noncurrent Liabilities		 59 32 50 92 45
Long-Term Debt		 50 21 29 77 2.18
Noncurrent Deferred & Payable Income Tax Liabilities		 - - 0.00 0.00 6.86
Noncurrent Employee Benefit Liabilities		 0.78 0.65 0.70 0.78 0.74
Other Noncurrent Operating Liabilities		 7.66 11 21 13 35
Total Equity & Noncontrolling Interests		 107 73 380 224 929
Total Preferred & Common Equity		 77 73 380 224 929
Total Common Equity		 77 73 380 224 929
Common Stock		 122 161 530 496 1,398
Retained Earnings		 -45 -89 -150 -272 -472
Other Equity Adjustments		 0.00 - 0.12 -0.08 2.71

Quarterly Balance Sheets for Abivax

No quarterly balance sheets for Abivax are available.

Annual Metrics And Ratios for Abivax

This table displays calculated financial ratios and metrics derived from Abivax's official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - 78,536,412.00
DEI Adjusted Shares Outstanding		 - - - - 78,536,412.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - -5.02
Growth Metrics		 - - - - -
Profitability Metrics		 - - - - -
Net Operating Profit after Tax (NOPAT)		 -33 -49 -99 -125 -202
Return On Investment Capital (ROIC_SIMPLE)		 - -42.38% -22.34% -38.68% -21.72%
Earnings before Interest and Taxes (EBIT)		 -47 -69 -141 -179 -289
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -47 -69 -140 -178 -288
Valuation Ratios		 - - - - -
Leverage & Solvency		 - - - - -
Liquidity Ratios		 - - - - -
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -75 -176 -137 -352
Efficiency Ratios		 - - - - -
Capital & Investment Metrics		 - - - - -
Invested Capital		 59 86 163 175 324
Increase / (Decrease) in Invested Capital		 0.00 26 77 12 150
Book Value per Share		 $5.01 $3.81 $8.83 $3.57 $14.66
Tangible Book Value per Share		 ($0.45) ($1.00) $4.39 $0.26 $7.97
Total Capital		 158 115 441 324 931
Total Debt		 51 42 61 100 2.18
Total Long-Term Debt		 50 21 29 77 2.18
Net Debt		 -18 13 -217 -50 -604
Capital Expenditures (CapEx)		 0.05 -0.33 16 0.66 -8.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.76 -6.68 -28 -27 -29
Debt-free Net Working Capital (DFNWC)		 62 22 251 122 578
Net Working Capital (NWC)		 61 0.80 218 100 578
Net Nonoperating Expense (NNE)		 15 16 65 57 192
Net Nonoperating Obligations (NNO)		 -47 13 -217 -50 -604
Total Depreciation and Amortization (D&A)		 0.34 0.52 0.78 1.14 1.26
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 43.07M 63.05M 69.53M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.43) ($2.90) ($5.67)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 43.07M 63.05M 69.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 62.93M 63.35M 78.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -38 -99 -125 -202
Debt Service Ratios		 - - - - -
Payout Ratios		 - - - - -

Quarterly Metrics And Ratios for Abivax

No quarterly metrics and ratios for Abivax are available.


Financials Breakdown Chart

Frequently Asked Questions About Abivax's Financials

When does Abivax's financial year end?

According to the most recent income statement we have on file, Abivax's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Abivax's net income changed over the last 4 years?

Abivax's net income appears to be on an upward trend, with a most recent value of -$394.45 million in 2025, rising from -$48.05 million in 2021. The previous period was -$182.43 million in 2024. Check out Abivax's forecast to explore projected trends and price targets.

What is Abivax's operating income?
Abivax's total operating income in 2025 was -$288.77 million, based on the following breakdown:
  • Total Gross Profit: -$6.10 million
  • Total Operating Expenses: $282.67 million
How has Abivax's revenue changed over the last 4 years?

Over the last 4 years, Abivax's total revenue changed from $0.00 in 2021 to -$6.10 million in 2025, a change of -609,567,800.0%.

How much debt does Abivax have?

Abivax's total liabilities were at $89.33 million at the end of 2025, a 44.3% decrease from 2024, and a 8.0% increase since 2021.

How much cash does Abivax have?

In the past 4 years, Abivax's cash and equivalents has ranged from $28.83 million in 2022 to $606.38 million in 2025, and is currently $606.38 million as of their latest financial filing in 2025.

How has Abivax's book value per share changed over the last 4 years?

Over the last 4 years, Abivax's book value per share changed from 5.01 in 2021 to 14.66 in 2025, a change of 192.8%.


Related Companies

Financial statements for NASDAQ:ABVX last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel